Research
Tau Therapy Shows Continued Benefit at 2 Years in Alzheimer's
The Brief
- Diranersen, an investigational antisense oligonucleotide that targets tau, continued to show benefits for 96 weeks.
- The data come from the open-label extension of the phase II CELIA trial.
- The results were reported in meeting coverage from CTAD.
Why it matters
It is early open-label extension data from a phase II trial, so it suggests a tau-targeting approach may be worth further study but does not establish efficacy. Science readers can use it to track whether tau-lowering therapies hold up in later, controlled trials.
Who’s affected
- Alzheimer's disease researchers
- clinicians and patients following Alzheimer's treatments
- #alzheimers
- #tau
- #antisense oligonucleotide
- #clinical trial
- #neurodegeneration
(MedPage Today) -- Diranersen, an investigational antisense oligonucleotide therapy that targets tau, continued to show benefits for 96 weeks, data from the open-label extension of the phase II CELIA trial suggested. At 2 years, diranersen continued...